SRR8518139
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.380
- MYC_TARGETS_V2+0.350
- MYC_TARGETS_V1+0.330
- SPERMATOGENESIS+0.320
- UNFOLDED_PROTEIN_RESPONSE+0.250
- G2M_CHECKPOINT+0.220
- MTORC1_SIGNALING+0.190
- OXIDATIVE_PHOSPHORYLATION+0.190
- KRAS_SIGNALING_DN+0.180
- UV_RESPONSE_UP+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.680
- INTERFERON_GAMMA_RESPONSE-0.560
- IL6_JAK_STAT3_SIGNALING-0.360
- ALLOGRAFT_REJECTION-0.340
- INFLAMMATORY_RESPONSE-0.330
- IL2_STAT5_SIGNALING-0.320
- KRAS_SIGNALING_UP-0.280
- UV_RESPONSE_DN-0.280
- COMPLEMENT-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | X97abcebb.f885.4eca.9af4.91a0adb97578 | — | cohortMD1 | 0.854 |
| 2 | SRR8518327 | — | E | 0.850 |
| 3 | R97 | — | — | 0.838 |
| 4 | BS_0HW7W7SD | Embryonal tumors | — | 0.834 |
| 5 | MBCProject_6109_T1C_RNA | — | B | 0.832 |
| 6 | TCGA-XF-A9ST-01A-11R-A42T-07 | — | — | 0.828 |
| 7 | TCGA-85-8664-01A-11R-2403-07 | — | cohortMD1 | 0.825 |
| 8 | SRR25617909 | — | E | 0.824 |
| 9 | 20120209.TNBC | — | E | 0.823 |
| 10 | MNG164 | — | — | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.320 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.220 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.110 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.080 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.050 | Inavolisib | — uncovered |